Category: Disclosures

[Disclosure] ALTEOGEN (196170) – Decision on Cash/In-Kind Dividend / 2026-02-11

February 11, 2026August 5, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN decided on a year-end cash dividend of KRW 371 per share for both common stock and preferred stock (RCPS) for FY2025. The total dividend payout amounts to approximately KRW 20.0B. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Disclosures, Bio & Healthcare

[Disclosure] LEENO Industrial (058470) – Decision on Cash/In-Kind Dividend / 2026-02-10

February 10, 2026August 4, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary LEENO Industrial has resolved on a year-end cash dividend of KRW 800 per common share for FY2025, totaling approximately KRW 60.72 billion. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of AGM Approval and Final Dividend Payment Date Disclosures…

Disclosures, Semiconductors

[Disclosure] LEENO Industrial (058470) – Change in Profit/Loss Structure over 30% (15% for Large Companies) / 2026-02-10

February 10, 2026August 4, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Driven by expanded customer orders and process improvements, LEENO Industrial’s FY2025 separate operating profit increased by 42.5% YoY to KRW 177.0 billion. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of External Audit Results and Final Annual Report Filing…

Disclosures, Semiconductors

[Disclosure] SK square (402340) – Change in Revenues or Profit/Loss Structure Exceeding 30% (15% for Large Corporations) / 2026-02-10

February 10, 2026July 31, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary SK square posted a 2025 operating profit of approximately KRW 8.80T, up 124.39% year-over-year, driven by increased earnings from key associate SK Hynix and improved profitability across its ICT portfolio. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Differences…

Semiconductors, Disclosures

[Disclosure] Hanwha Ocean (042660) – (Correction) Other Major Management Matters (Voluntary Disclosure) / 2026-02-10

February 10, 2026August 8, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 Executive Summary Hanwha Ocean disclosed that liquidated damages of KRW 28.0B regarding the transferred plant business contract will be finalized in February 2026, and Hanwha Corporation is expected to compensate Hanwha Ocean for the corresponding KRW 28.0B under a prior agreement. 📊 [Key Disclosure Details & Financial Summary]…

Disclosures, Shipbuilding

[Disclosure] Celltrion (068270) – Additional Listing (Exercise of Stock Options) / 2026-02-10

February 10, 2026August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is additionally listing 87,292 common shares on February 13, 2026, following the exercise of stock options by employees. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Additional Listing Execution on Scheduled Date (February 13, 2026) This disclosure…

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – Application for Amendment of Phase 3 Clinical Trial Plan for CT-P55 in Europe (Correction) / 2026-02-10

February 10, 2026August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has disclosed the previously withheld subject count (153 patients) for the Phase 3 clinical trial plan amendment application for CT-P55 (Cosentyx biosimilar candidate) in Europe through a corrective filing following regulatory approval. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – Approval for Amendment of Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in Europe (Part 1 & 2) / 2026-02-10

February 10, 2026August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has received final approval from the European Medicines Agency (EMA) for the amendment of the Phase 3 clinical trial plan (Part 1 & Part 2) for CT-P55 (Cosentyx biosimilar candidate). 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…

Disclosures, Bio & Healthcare

[Disclosure] Jusung Engineering (036930) – Change in Sales or Profit/Loss Structure by More Than 30% (15% for Large Companies) / 2026-02-10

February 10, 2026August 3, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Jusung Engineering reported FY2025 consolidated revenue of KRW 310.7B (-24.1% YoY) and operating profit of KRW 31.3B (-67.8% YoY) due to increased R&D investments for future growth drivers. 📊 [Key Disclosure Contents & Summary Metrics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of External Audit…

Semiconductors, Disclosures

[Disclosure] Jusung Engineering (036930) – Decision on Cash / Dividend in Kind / 2026-02-10

February 10, 2026August 3, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Jusung Engineering has decided to pay a year-end cash dividend of KRW 53 per common share (totaling approx. KRW 2.42B) for the FY2025 fiscal year. 📊 [Key Disclosure Contents & Summary Metrics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Shareholders’ Meeting Approval and Dividend…

Semiconductors, Disclosures